Astrazeneca (AZN) Interest Coverage Ratio (2009 - 2026)
Astrazeneca (AZN) posted quarterly Interest Coverage Ratio of 10.8 for Q1 2026, down 2.63% year-over-year from 11.1 in Q1 2025, and down 75.59% on a QoQ basis from 6.15 in Q4 2025.
Astrazeneca (AZN) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Astrazeneca (AZN) has reported Interest Coverage Ratio for 18 consecutive years, with 10.8 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 2.63% year-over-year to 10.8; the TTM figure through Mar 2026 stood at 8.18 (down 29.96% YoY), while the FY2025 annual figure was 8.11, up 41.28% from the prior year.
- Interest Coverage Ratio came in at 10.8 for Q1 2026 at Astrazeneca, down from 6.15 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 1.73 in Q2 2022, with the low at 10.8 in Q1 2026.
- Average Interest Coverage Ratio over 5 years is 5.78, with a median of 5.7 recorded in 2023.
- The largest YoY upside for Interest Coverage Ratio was 49.87% in 2022 against a maximum downside of 449.68% in 2022.
- Year by year, Interest Coverage Ratio stood at 3.04 in 2022, then climbed by 8.75% to 2.77 in 2023, then plunged by 71.15% to 4.75 in 2024, then dropped by 29.65% to 6.15 in 2025, then plunged by 75.59% to 10.8 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 10.8, 6.15, and 8.26 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 23.39 |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -10.80 |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.80 |
| Dec 31, 2025 | -6.15 |
| Sep 30, 2025 | -8.26 |
| Jun 30, 2025 | -7.99 |
| Mar 31, 2025 | -10.53 |
| Dec 31, 2024 | -4.75 |
| Sep 30, 2024 | -4.61 |
| Jun 30, 2024 | -6.20 |
| Mar 31, 2024 | -7.54 |
| Dec 31, 2023 | -2.77 |
| Sep 30, 2023 | -4.98 |
| Jun 30, 2023 | -5.70 |
| Mar 31, 2023 | -6.98 |
| Dec 31, 2022 | -3.04 |
| Sep 30, 2022 | -3.67 |
| Jun 30, 2022 | -1.73 |
| Mar 31, 2022 | -2.61 |
| Dec 31, 2021 | 0.87 |
| Sep 30, 2021 | 5.00 |
| Jun 30, 2021 | -3.46 |